Molecular Delivery of Growth Hormone

Then we introduce it to the negatively charged recombinant hGH and the new molecular structure reclaims its static imbalance by literally enveloping the hGH molecule by static force. What remains is a positively charged molecular structure that is ready for use.

Now, since the molecule is positively charged and the human body is negative, when introduced to the oral mucosal tissues, the polarity of the new molecule stretches like two opposing magnetic fields. The new molecule elongates and as a result it becomes very thin much like a string of spaghetti, and because the hGH molecule within the 191 amino acid structure is wound like a conch shell with few crossovers (conical), it now can retain its integrity and be thin enough to pass through the mucosal walls and into the system and bypass the process of liver metabolism, which would destroy the HGH molecule.

Because of this procedure, relatively small dosages in nanograms amounts can have the efficacy similar to that of injected hGH. A significant benefit of this system is that it encourages the anterior pituitary to secrete exacting supplies that are commensurate with individual requirements of independent subjects. The body's own cellular memory is what sets up the transmissions of neuro transmitters and neuro receptor sites and guides the ambient hormonal chain in the creation and replication of natural body function.

Growth hormone has a very stable shelf life when in a dry, powdered form. So another challenge is the HGH molecule itself, once in a hydrophilic state (constituted with water) the molecule begins to immediately break down due to oxidization. This is solved by the encapsulation process which protects the HGH molecule from oxidation via encasing each HGH molecule in an ionized polymer known as a delivery vector. This provides a very stable shelf life for the growth hormone molecule with 100% integrity after two years and 90% integrity after three years at room temperature.

Transmucosal Polymeric Molecular Delivery (delivery vector)

The means by which a molecule or compound is introduced to the body is as important as the compound itself that is being delivered. It is imperative that the exogenous substance administered within the polymer matrix to the blood stream be maintained at a level that can provide maximum therapeutic benefit.

When a therapeutic compound is created, one must consider how to transport the compound to the appropriate receptor sites. This is not a trivial issue; in some cases, the development of the delivery system can be as difficult as the therapeutic compound itself.

Controlled release (DDS) serves two functions. The first, delivery, involves the transport of the therapeutic compound into the body and to specific receptor sites. This can be accomplished in a number of ways intravenously, orally, transdermally and via the oral mucosa or buccal ducts.

The second function is that of controlled release. This describes the rate at which the therapeutic compound is made to the body once it has been delivered.

Most controlled release systems fall into one of three categories: diffusion, solvent activated release, and polymeric degradation.

In a diffusion system, the therapeutic compound is either encapsulated in a polymer membrane or suspended within a polymer matrix. Typically the course of events is as follows: water diffuses into the membrane or matrix, the therapeutic compound is then diffused out of the polymer.

Solvent activated systems use one of several mechanisms. The most common employs a semi permeable membrane that contains a small hole. Within the membrane there is a high concentration of an osmotic agent that causes water to enter through the membrane. The therapeutic compound is then forced out.

Polymeric degradation and with the diffusion method, the therapeutic compound is contained within the polymer membrane or matrix. The polymer is designed to degrade and release the therapeutic compound at a specific location in the body. As the polymer degrades, the therapeutic compound is released and made available to the body.

Degradation occurs via three major mechanisms. In the first, water soluble polymers are made insoluble by cross linking them together. When the cross-links are broken at some point in the body, the polymer will dissolve. In the second mechanism, water insoluble polymers are made soluble by hydrolysis or ionization of side groups. Finally, the third approach applies the use of insoluble polymers that are cleaved into soluble monomers. Many degradation systems use a combination of these mechanisms.

Many matrix systems use what is known as bulk degradation. This means that degradation occurs throughout the polymer structure in a rather random fashion. The erosion rate is dependent upon the volume of the matrix rather than its thickness. Other matrix systems use surface degradation other than bulk degradation. This polymer is highly hydrophobic yet contain water labile linkages. Thus, diffusion of water into the matrix and internal degradation are minimized. The therapeutic compound release rate is proportional to the polymer degradation rate; with the proper surface geometry, zero order degradation kinetics is possible.

The group of poly(lactide) polymers and the lactide/(glycolide) copolymers has a proven track record concerning their biocompatibility. They ultimately degrade into lactic acid and glycolic acid, nontoxic components that are consequently excreted via the Krebs cycle as water and carbon dioxide. There are many other compounds that can be used for polymeric degradation. Copolymers such as styrene and hyrdoxymethacrylate, calcium pectinate, (a water soluble a (1 4) linked polysaccharide, consisting of D galacturonic monomers with several methyl ester constituents). Other polymers are hydroxypropl methylcellulose acetate succinate. The D galacturonic units that are cleaved from the polymer are water soluble , they may be then absorbed by the body and enter the metabolic pathway. As the matrix degrades, the therapeutic compound is then made available to the body.

An injection of one international unit (i.u.) is equivalent to 350,000 nanograms. 50,000 nanograms is the approximate amount produced by the body in a 24-hour period. This means that an injection is 7 times the quantity normally produced by the body. Once injected, this flood of HGH goes into the bloodstream and is absorbed by the liver. All unused excess is destroyed or diluted within the blood. Clearly, this injection dosage is far in excess of the body's natural production of GH. As a result, it falsely simulates the body's production requirement of GH, thereby shutting down the body's natural pituitary production (absolute or relative refractory) and increasing the antagonist hormone somatostatin (the anti-hgh hormone).

A daily dose of AEON 5000 Ingestible spray supplies an appropriate amount of 5000 nanograms of GH per day. This means there is no over-stimulation of the pituitary and thus there is no shutdown of your body's own natural production activity of GH or false signaling to increase somatostatin production. AEON 5000 actually works to enable your pituitary to produce more of its own GH. The longer AEON 5000 GH is used, the younger your body can become.

Due to the natural decline of HGH production with age, daily use for life of hGH has been proven to significantly increase one's quality of life. Furthermore, along with daily use of hGH and concurrent inhibition of somatostatin (the anti HGH hormone), the benefits of daily rGH usage are significantly amplified.

AEON is Bio-Identical Growth Hormone

Over 90% of products marketed as HGH, CONTAIN NO ACTUAL GROWTH HORMONE. They simply contain inexpensive amino acids and/or minerals and other pseudo-scientific concoctions that purportedly stimulate HGH release.

AEON is distinctly different from so-called HGH "boosters", "stimulators", "promoters", "precursors", "secretagogues", "effervescents", "IGF-1 maximizers", "supporting compounds and synergists", "amino acid polymer matrixes", and other similar inferior products-whether found in the form of a pill, powder, patch, liquid, capsule or spray.

Those products contain NO HGH, even though their labels are carefully worded to make you believe that they do (Some companies do admit this, but only in the fine print). These inferior products, all calling themselves HGH, are all advertised as if they were true HGH and this further confuses the issue. These companies want to claim and associate themselves with the headlines and benefits of true HGH, but there's one very big problem...their products are NOT HGH. The lack of a true and effective product is purposely hidden behind all of their hype.

Most of these "stimulator" type products are questionable at best. The technological sophistication required to have one's body metabolically transport and deliver a large molecule such as HGH to the receptor sites of your cells is out of the reach of virtually all supplement companies, and even many pharmaceutical corporations.

AEON, REAL growth hormone

AEON is the highest quality, non-prescription somatotropin (GH) replenishing formulation available from any source. It's foundational material is recombinant somatotropin (HGH naturally synthesized in a pharmaceutical laboratory) from natural sources. AEON uses NO animal extracts and contains NO Brain glandulars, NO Steroids, NO Bovine (cow) and NO Porcine (pig) products.

AEON's formula is entirely unique

The key with GH is that its molecular structure follows an exact sequence, which must be kept intact for effective absorption and assimilation. At AARL, we uniquely provide not only the finest formulation, we also provide the precise delivery vector (technological transport and delivery system) necessary to bring this exact sequence and strength of true GH. No one else can provide this for you. Our specialized formulation effectively stabilizes the HGH in a liquid solution so that the full strength of GH is delivered to you.